Analyst Price Target is $6.75
▲ +519.27% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Molecular Templates in the last 3 months. The average price target is $6.75, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 519.27% upside from the last price of $1.09.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Molecular Templates. This Buy consensus rating has held steady for over two years.
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.